Ucb SA
Other Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Ucb SA
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Ucb SA
XBRU:UCB
Other Receivables
€71m
CAGR 3-Years
-5%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Financiere de Tubize SA
XBRU:TUB
Other Receivables
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hyloris Pharmaceuticals SA
XBRU:HYL
Other Receivables
€508k
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Ucb SA
Glance View

Market Cap
46.1B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
238.26 EUR
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Ucb SA's Other Receivables?
Other Receivables
71m EUR

Based on the financial report for Jun 30, 2025, Ucb SA's Other Receivables amounts to 71m EUR.

What is Ucb SA's Other Receivables growth rate?
Other Receivables CAGR 5Y
18%

Over the last year, the Other Receivables growth was 42%. The average annual Other Receivables growth rates for Ucb SA have been -5% over the past three years , 18% over the past five years .

Back to Top